On April 2, Fosun Pharmaceutical holding company Shanghai Fuhong Hanlin Biotechnology Co., Ltd
(hereinafter referred to as "Fuhong Hanlin") formally received the approval document for clinical trial of recombinant human mouse chimeric anti-CD20 monoclonal antibody injection issued by the State Food and drug administration
As the macromolecular R & D platform of Fosun Pharmaceutical, for more than four years, Fosun Hanlin has been adhering to the R & D concept of international standards, quality and efficiency priority, and implementing the R & D strategy of biological macromolecules
This approval is the first clinical approval of Fuhong Hanlin since its establishment, and also the first clinical approval of monoclonal antibody drugs obtained by Fosun Pharmaceutical holding member enterprises
It is reported that Fuhong Hanlin has so far completed the clinical registration application for 4 monoclonal antibody varieties and 5 indications
Fosun Pharmaceutical always takes independent innovation as the source power of enterprise development
The company continues to pay attention to innovation and R & D, improve the drug R & D innovation system of "combination of imitation and innovation"
By continuously increasing investment in the "4 + 1" R & D platform, Fosun Pharmaceutical fully supports R & D innovation and promotes the listing of new products
As a national enterprise technology center, the company has established an efficient international R & D team in Shanghai, Chongqing and the United States.